Zimmer Biomet (NYSE:ZBH – Get Free Report) will likely be announcing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of $2.01 per share and revenue of $2.1349 billion for the quarter. Investors can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:30 AM ET.
Zimmer Biomet Stock Performance
Shares of ZBH stock opened at $94.20 on Monday. The firm has a market capitalization of $18.22 billion, a PE ratio of 24.47, a price-to-earnings-growth ratio of 2.77 and a beta of 0.45. The firm has a fifty day simple moving average of $88.84 and a two-hundred day simple moving average of $89.85. The company has a current ratio of 1.73, a quick ratio of 0.95 and a debt-to-equity ratio of 0.50. Zimmer Biomet has a 12 month low of $79.12 and a 12 month high of $108.29.
Zimmer Biomet Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Friday, July 31st. Shareholders of record on Thursday, June 25th were paid a dividend of $0.24 per share. The ex-dividend date was Thursday, June 25th. This represents a $0.96 annualized dividend and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is 24.94%.
Analysts Set New Price Targets
Read Our Latest Research Report on ZBH
Insider Activity at Zimmer Biomet
In related news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the transaction, the insider directly owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. This trade represents a 15.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.28% of the company’s stock.
Hedge Funds Weigh In On Zimmer Biomet
A number of large investors have recently made changes to their positions in ZBH. DV Equities LLC bought a new stake in shares of Zimmer Biomet during the 4th quarter valued at $25,000. Gen Wealth Partners Inc bought a new stake in shares of Zimmer Biomet during the fourth quarter valued at about $31,000. Headlands Technologies LLC bought a new position in shares of Zimmer Biomet in the second quarter valued at approximately $37,000. EFG International AG purchased a new position in Zimmer Biomet during the fourth quarter valued at approximately $55,000. Finally, Mpwm Advisory Solutions LLC purchased a new stake in Zimmer Biomet in the 3rd quarter worth approximately $65,000. 88.89% of the stock is owned by institutional investors.
Zimmer Biomet Company Profile
Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.
The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.
Read More
- Five stocks we like better than Zimmer Biomet
- 3 Humanoid Robot ETFs to Ride a Speculative Trend
- Bearish Pressure Is Building Around These 3 Stocks
- 3 Low-Volatility Plays Quietly Making a Name For Themselves
- ASML’s Dividend Growth Adds a Quiet Income Angle to Its AI Chip Story
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.
